ITEM VIEW

Amyloidosis: A changing clinical perspective

dc.contributor.authorJacobs P.
dc.contributor.authorRuff P.
dc.contributor.authorWood L.
dc.contributor.authorMoodley D.
dc.contributor.authorMansvelt E.
dc.date.accessioned2011-05-15T16:16:31Z
dc.date.available2011-05-15T16:16:31Z
dc.date.issued2007
dc.identifier.citationHematology
dc.identifier.citation12
dc.identifier.citation2
dc.identifier.issn10245332
dc.identifier.other10.1080/10245330701214350
dc.identifier.urihttp://hdl.handle.net/10019.1/13815
dc.description.abstractPrimary amyloidosis is a plasma cell dyscrasia characterised by excess production of abnormal immunoglobulin light chains with their subsequent accumulation in kidneys, heart, liver as well as gastrointestinal tract and bone marrow 1-21, 2. These tissue deposits take the form of a fibrillar protein which damages the involved organ in proportion to the extent of the infiltration and roughly parallels the duration of the disease. Most cases have evidence of the underlying lymphoplasmacytoid neoplasm recognisable in two ways. Firstly, the monoclone appears in the serum [2]. Secondly is a morphologically and immunohistochemically distinctive cellular infiltrate in the bone marrow [3] that has a specific microscopic and ultrastructural pattern [4-5]. Interestingly occasional patients, who survive long enough, may progress to multiple myeloma [6] but the correlation is variable [7].
dc.subjectamyloid protein
dc.subjectcyclophosphamide
dc.subjectdoxorubicin
dc.subjectetoposide
dc.subjectimmunoglobulin light chain
dc.subjectmelphalan
dc.subjectphenylalanine
dc.subjectprednisone
dc.subjectvincristine
dc.subjectadult
dc.subjectaged
dc.subjectamyloidosis
dc.subjectarticle
dc.subjectblood analysis
dc.subjectcancer combination chemotherapy
dc.subjectcell infiltration
dc.subjectcell ultrastructure
dc.subjectclinical article
dc.subjectcorrelation analysis
dc.subjectdisease duration
dc.subjectfemale
dc.subjecthematopoietic stem cell transplantation
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunoglobulin production
dc.subjectimmunohistochemistry
dc.subjectmale
dc.subjectmorbidity
dc.subjectmortality
dc.subjectmultiple myeloma
dc.subjectpriority journal
dc.subjectprotein blood level
dc.subjectprotein localization
dc.subjectrisk assessment
dc.subjectsurvival
dc.subjectsurvival time
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjectAdult
dc.subjectAged
dc.subjectAmyloidosis
dc.subjectAntibodies, Monoclonal
dc.subjectBone Marrow
dc.subjectBone Marrow Transplantation
dc.subjectColchicine
dc.subjectDiagnosis, Differential
dc.subjectDisease Management
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunotherapy
dc.subjectLymphoproliferative Disorders
dc.subjectMale
dc.subjectMelphalan
dc.subjectMethylprednisolone
dc.subjectMiddle Aged
dc.subjectPlasma Cells
dc.subjectPrednisone
dc.subjectRadioimmunotherapy
dc.subjectSouth Africa
dc.subjectSurvival Rate
dc.titleAmyloidosis: A changing clinical perspective
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW